Text Size:AAA

NME1 / NDKA Antibody (FITC), Mouse MAb

DatasheetSpecific ReferencesReviewsRelated ProductsProtocols
NME1Antibody Product Information
Immunogen:Recombinant Human NME1 / NDKA protein (Catalog#11615-H07E)
Clone ID:01
Ig Type:Mouse IgG1
Concentration:10 μl/Test, 0.1 mg/ml
Formulation:Aqueous solution containing 0.5% BSA and 0.09% sodium azide
Preparation:This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human NME1 / NDKA (rh NME1 / NDKA; Catalog#11615-H07E; NP_000260.1; Ala 2-Glu 152) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.
NME1Antibody Usage Guide
Specificity:Human NME1 / NDKA
Application:FCM
Storage:This antibody is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze !
Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.
Images
NME1 / NDKA Antibody (FITC), Mouse MAb, Flow cytometric
[Click to enlarge image]
Caption:
Flow cytometric analysis of Human NME1 expression in HeLa cells. The cells were treated according to manufacturer’s manual (BD Pharmingen™ Cat. No. 554714), and then stained with FITC Mouse anti-NME1 (11615-MM01-F). The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells.
Background

NME1, also known as Nucleoside Diphosphate Kinase A (NDK-A), or NM23-H1, belongs to the NDK family. NM23-H1 is known to have a metastasis suppressive activity in many tumor cells. Recent studies have shown that the interacting proteins with NM23-H1 which mediate the cell proliferation, may act as modulators of the metastasis suppressor activity. The interacting proteins with NM23-H1 can be classified into 3 groups. The first group of proteins can be classified as upstream kinases of NM23-H1 such as CKI and Aurora-A/STK15. The second group of proteins acts as downstream effectors for the regulation of specific gene transcriptions, GTP-binding protein functions, and signal transduction in Erk signal cascade. The third group of proteins can be classified as bi-directionally influencing binding partners of NM23-H1. As a result, the interactions with NM23-H1 and binding partners have implications in the biochemical characterization involved in metastasis and tumorigenesis. NDKA is increased in human postmortem cerebrospinal fluid (CSF), a model of global brain insult, suggesting that measurement in CSF and, more importantly, in plasma may be useful as a biomarker of stroke. Additionally, NM23-H1 significantly reduces metastasis without effects on primary tumor size and was the first discovered metastasis suppressor gene.

References
  • Allard L, et al. (2005) PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin Chem. 51(11): 2043-51.
  • Steeg PS, et al. (2008) Clinical-translational approaches to the Nm23-H1 metastasis suppressor. Clin Cancer Res. 14(16): 5006-12.
  • Kim HD, et al. (2009) Regulators affecting the metastasis suppressor activity of Nm23-H1. Mol Cell Biochem. 329(1-2): 167-73.
  • Related Products
    Product nameProduct name
    Size / Price
    Catalog:11615-MM01-F-50
    List Price: $130.00  (Save $0.00)
    Price:$130.00      [How to order]
    AvailabilityIn Stock
    Images
    • NME1 / NDKA Antibody (FITC), Mouse MAb, Flow cytometric
    Recently Viewed Items
      Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"